Taro Recalls Kamedis Dandruff Care Kits Due to Low Active Ingredient
Taro Pharmaceuticals is recalling 17,100 kits of Kamedis Bio-Herbal Dandruff Care System because the active ingredient, zinc pyrithione, was found to be subpotent.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The recall is classified as FDA Class III, which indicates the product is unlikely to cause adverse health consequences. The hazard is a subpotent active ingredient, which is a documentation and efficacy issue rather than a direct safety risk like contamination or injury.
Plain-English summary
Taro Pharmaceuticals U.S.A., Inc. is recalling 17,100 kits of the Kamedis BIO-HERBAL DANDRUFF CARE THERAPEUTIC 2-STEP DANDRUFF CARE SYSTEM. The affected products include Step 1 Pre-Treat Concentrated Botanical Scalp Lotion (0.1% Pyrithione Zinc) and Step 2 Cleanse Concentrated Botanical Dandruff Shampoo (1.0% Pyrithione Zinc). The recall is due to out-of-specification assay values on stability for the active ingredient, zinc pyrithione, indicating the product is subpotent.
The affected lots are E601, E602, E603, E604, E608, and E609 with an expiration date of September 2017, and lots E610 and E611 with an expiration date of October 2017. These products were distributed nationwide.
Consumers who have these products should stop using them and contact Taro Pharmaceuticals or their healthcare provider for further instructions.
The recalled product
- Product
- Kamedis BIO-HERBAL DANDRUFF CARE THERAPEUTIC 2-STEP DANDRUFF CARE SYSTEM - Kamedis Bio-Herbal Dandruff Care 0.1% PYRITHIONE ZINC, STEP 1 PRE-TREAT Concentrated Botanical Scalp Lotion (0.1% Pyrithione Zinc) 4.20 FL OZ (125mL) (NDC 51672-2126-0) and STEP 2 CLEANSE Concentrated Bot
- Manufacturer
- Taro Pharmaceuticals U.S.A., Inc.
- Hazard
- Affected units
- 17,100
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (8)
- Lot #: E601
- E602
- E603
- E604
- E608
- E609 - Exp. September 2017
- E610 E611
- Exp. October 2017
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Taro Pharmaceuticals U.S.A., Inc.
See all →- ModerateHydrocortisone & Acetic Acid Otic Solution Recalled for Potency and Impurity Failures
FDA (Drugs) · 2024-08-21
- ModerateClotrimazole and Betamethasone Topical Cream Recalled for Failed Potency Specifications
FDA (Drugs) · 2022-04-06
- SevereClobetasol Propionate Ointment Recalled for Microbial Contamination
FDA (Drugs) · 2022-01-19
- HighTaro Recalls Nortriptyline Hydrochloride Capsules Due to Manufacturing Deviations
FDA (Drugs) · 2021-02-10
- ModerateTaro Recalls Rite Aid Clotrimazole Cream Due to Impurity
FDA (Drugs) · 2020-12-23
Same hazard · subpotent drug
See all →- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- ModerateAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02